We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A majority of physicians have some kind of relationship with the pharmaceutical industry, such as receiving gifts of food and drug samples, despite efforts to regulate such interactions, a new study reported. Read More
Continuing medical education (CME) programs may not be independent from inappropriate influence from the pharmaceutical industry, Senate Finance Committee Chairman Max Baucus (D-Mont.) and Sen. Chuck Grassley (R-Iowa) said. Read More
Amgen plans to announce results from an Aranesp small-cell lung cancer clinical trial when the firm reports first quarter earnings April 23, the company announced. Read More
U.S. sales of Johnson & Johnson's (J&J) erythropoiesis-stimulating agent (ESA) Procrit remained steady during the fourth quarter of 2007 despite recent drug safety issues associated with the use of ESAs. Read More
MedImmune is looking into a potential sale of the company, as the board of directors authorized management to evaluate third-party interest in an acquisition that would provide a “better value” for its stockholders than continuing its business on a standalone basis.
Teva Pharmaceutical’s multiple sclerosis (MS) agent Copaxone is a better treatment for patients with relapsing-remitting MS compared with interferon beta drug products, a recent study found.
Ortho-McNeil Pharmaceutical, a subsidiary of Johnson & Johnson, has recalled an estimated 200,000 units of anti-fungal Grifulvin V because of two reports that glass fragments were found in bottles of the oral suspension, the firm announced April 10.
PhRMA voiced opposition to proposed legislation that would create a pathway for the FDA to approve follow-on biologics because it will not ensure patient safety and will hinder innovation, the group said. While PhRMA does support a regulatory pathway for the products, the proposed bill does not ensure the best process for the FDA or consumers, the group added.
Abbott Laboratories’ new Barceloneta, Puerto Rico, manufacturing facility will be the primary production facility for TNF inhibitor Humira, the firm announced April 10.
Following an eventful fourth quarter in 2006, the generic drug industry is expected to have a favorable year in 2007, Arthur Wong, an analyst with Standard & Poor’s, said in a new report.